CY1111452T1 - Αλογονωμενες πυραζολο [1,5-α]πυριμιδινες, διεργασιες, χρησεις ως προσδεμα υποδοχεα gaba-a, συνθεσεις και ενδιαμεσα - Google Patents

Αλογονωμενες πυραζολο [1,5-α]πυριμιδινες, διεργασιες, χρησεις ως προσδεμα υποδοχεα gaba-a, συνθεσεις και ενδιαμεσα

Info

Publication number
CY1111452T1
CY1111452T1 CY20101100750T CY101100750T CY1111452T1 CY 1111452 T1 CY1111452 T1 CY 1111452T1 CY 20101100750 T CY20101100750 T CY 20101100750T CY 101100750 T CY101100750 T CY 101100750T CY 1111452 T1 CY1111452 T1 CY 1111452T1
Authority
CY
Cyprus
Prior art keywords
intermediates
processes
hologenized
pyrozolo
pyrimides
Prior art date
Application number
CY20101100750T
Other languages
English (en)
Inventor
Luís Anglada
Albert Palomer
Antonio Guglietta
Original Assignee
Ferrer Internacional, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional, S.A. filed Critical Ferrer Internacional, S.A.
Publication of CY1111452T1 publication Critical patent/CY1111452T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση παρέχει καινοφανείς αλογονωμένες πυραζολο[1,5-a]πυριμιδίνες με τύπο (I) όπου τα R, R1, Χ και Υ έχουν διαφορετικές έννοιες, και φαρμακευτικώς αποδεκτά άλατα αυτών. Οι ενώσεις με τύπο (I) είναι χρήσιμες για την αντιμετώπιση ή πρόληψη άγχους, επιληψίας, και διαταραχών ύπνου περιλαμβάνοντας αϋπνία, και για την επαγωγή καταστολής-ύπνωσης, αναισθησίας, ύπνου και χαλάρωσης μυών. Η εφεύρεση επίσης παρέχει συνθετικές διαδικασίες για την παρασκευή των προαναφερθεισών ενώσεων και ορισμένα ενδιάμεσα, όπως επίσης και τα ίδια τα ενδιάμεσα.
CY20101100750T 2005-06-21 2010-08-11 Αλογονωμενες πυραζολο [1,5-α]πυριμιδινες, διεργασιες, χρησεις ως προσδεμα υποδοχεα gaba-a, συνθεσεις και ενδιαμεσα CY1111452T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69286605P 2005-06-21 2005-06-21
EP05105478A EP1736475A1 (en) 2005-06-21 2005-06-21 Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
EP06763737A EP1899343B1 (en) 2005-06-21 2006-06-15 Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates

Publications (1)

Publication Number Publication Date
CY1111452T1 true CY1111452T1 (el) 2015-08-05

Family

ID=35311853

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100750T CY1111452T1 (el) 2005-06-21 2010-08-11 Αλογονωμενες πυραζολο [1,5-α]πυριμιδινες, διεργασιες, χρησεις ως προσδεμα υποδοχεα gaba-a, συνθεσεις και ενδιαμεσα

Country Status (25)

Country Link
US (3) US8530482B2 (el)
EP (2) EP1736475A1 (el)
JP (1) JP5010591B2 (el)
KR (1) KR101465802B1 (el)
CN (1) CN101243089B (el)
AR (1) AR054785A1 (el)
AT (1) ATE467635T1 (el)
AU (1) AU2006261025B2 (el)
BR (1) BRPI0612075A2 (el)
CA (1) CA2612726C (el)
CY (1) CY1111452T1 (el)
DE (1) DE602006014272D1 (el)
DK (1) DK1899343T3 (el)
ES (1) ES2345999T3 (el)
HK (1) HK1116184A1 (el)
MX (1) MX2007016340A (el)
NO (1) NO339973B1 (el)
PE (1) PE20070071A1 (el)
PL (1) PL1899343T3 (el)
PT (1) PT1899343E (el)
RU (1) RU2478101C2 (el)
SI (1) SI1899343T1 (el)
TW (1) TWI382985B (el)
UY (1) UY29618A1 (el)
WO (1) WO2006136530A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
EP1996594A2 (en) * 2006-03-17 2008-12-03 Wyeth a Corporation of the State of Delaware Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
EP1884516A1 (en) * 2006-08-04 2008-02-06 Ferrer Internacional, S.A. Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions
EP1956021A1 (en) 2006-10-11 2008-08-13 Ferrer Internacional, S.A. Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound
EP1918290A1 (en) * 2006-10-11 2008-05-07 Ferrer Internacional, S.A. Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide
EP1921079A1 (en) * 2006-11-08 2008-05-14 Ferrer Internacional, S.A. Amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide
AR075009A1 (es) * 2009-01-13 2011-03-02 Interquim Sa Procedimiento para la preparcion de la n-(5-(3-dimetilamino-acriloil=-2-fluoro-fenil) -n-metil-acetamida y de la n-(2-fluoro-5-(3-tiofeno=-2- carbonil pirazolo (1,5-a) pirimidin -7-il) fenil)-n- metil- acetamida y compuesto n-(5-acetil-2-fluorofenil)-n-metil-acetamida
US9624184B2 (en) 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
KR20030082982A (ko) * 2001-03-14 2003-10-23 그뤼넨탈 게엠베하 치환된 피라졸로피리미딘 및 티아졸로피리미딘
JP2005516955A (ja) * 2001-12-21 2005-06-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト アロイル・ピリジノン化合物
ES2222813B1 (es) * 2003-07-24 2005-12-16 Ferrer Internacional, S.A. N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados.
WO2006033795A2 (en) * 2004-09-17 2006-03-30 Wyeth Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
WO2006033796A1 (en) * 2004-09-17 2006-03-30 Wyeth SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME
CN100528875C (zh) * 2005-02-18 2009-08-19 美德（江西）生物科技有限公司 无结晶型态的印地普隆及其制备方法
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates

Also Published As

Publication number Publication date
DE602006014272D1 (de) 2010-06-24
SI1899343T1 (sl) 2010-09-30
US20160368912A9 (en) 2016-12-22
DK1899343T3 (da) 2010-09-06
PL1899343T3 (pl) 2010-10-29
CA2612726A1 (en) 2006-12-28
PT1899343E (pt) 2010-08-17
JP5010591B2 (ja) 2012-08-29
TWI382985B (zh) 2013-01-21
EP1899343A1 (en) 2008-03-19
CA2612726C (en) 2013-10-01
ATE467635T1 (de) 2010-05-15
UY29618A1 (es) 2006-10-31
EP1899343B1 (en) 2010-05-12
NO339973B1 (no) 2017-02-27
RU2008101371A (ru) 2009-07-27
HK1116184A1 (en) 2008-12-19
CN101243089B (zh) 2011-07-06
US10072000B2 (en) 2018-09-11
PE20070071A1 (es) 2007-02-01
WO2006136530A1 (en) 2006-12-28
MX2007016340A (es) 2008-03-10
KR101465802B1 (ko) 2014-11-27
NO20080393L (no) 2008-03-10
AU2006261025B2 (en) 2011-09-08
BRPI0612075A2 (pt) 2010-10-19
US20090111848A1 (en) 2009-04-30
US8530482B2 (en) 2013-09-10
CN101243089A (zh) 2008-08-13
JP2008543913A (ja) 2008-12-04
AU2006261025A1 (en) 2006-12-28
EP1736475A1 (en) 2006-12-27
KR20080032104A (ko) 2008-04-14
US20130331401A1 (en) 2013-12-12
AR054785A1 (es) 2007-07-18
TW200726769A (en) 2007-07-16
US20130331610A1 (en) 2013-12-12
RU2478101C2 (ru) 2013-03-27
ES2345999T3 (es) 2010-10-07

Similar Documents

Publication Publication Date Title
CY1111452T1 (el) Αλογονωμενες πυραζολο [1,5-α]πυριμιδινες, διεργασιες, χρησεις ως προσδεμα υποδοχεα gaba-a, συνθεσεις και ενδιαμεσα
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
CY1113209T1 (el) Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CY1111316T1 (el) Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
PE20030129A1 (es) Imidazotriazinas
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
MY131518A (en) 6-substituted pyrido-pyrimidines
MX2007004250A (es) Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos.
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
HK1068622A1 (en) Novel heteroaryl derivatives, their preparation and use
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
TW200833665A (en) 1H-quinolin-4-one compounds, processes, uses and compositions
CY1110757T1 (el) Πυραζολο-[1,5-α]πυριμιδινες, διεργασιες, χρησεις και συνθeσεις
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
CY1115760T1 (el) Τικαγρελορη για την θεραπευτικη αγωγη ανευρυσματων κοιλιακης αορτης
TW200500365A (en) Preparation of substituted quinoxalines
UY30066A1 (es) Hidrazidas del acido imidazo(1,2-a) piridin-3-il-acético, procesos, usos y composiciones
MXPA05010633A (es) Compuestos de pirrolo(1,2-b)piridazina y su uso como antagonistas del receptor de factor liberador de corticotropina-1.
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila